From DREAM to REALITI-A and beyond: Mepolizumab for the treatment of eosinophil-driven diseases.

ABSTRACT: Effective treatment of inflammatory diseases is often challenging owing to their heterogeneous pathophysiology. Understanding of the underlying disease mechanisms is improving and it is now clear that eosinophils play a complex pathophysiological role in a broad range of type 2 inflammatory diseases. Standard of care for these conditions often still includes oral corticosteroids (OCS) and/or cytotoxic immune therapies, which are associated with debilitating side effects. Selective, biological eosinophil-reducing agents provide treatment options that improve clinical symptoms associated with eosinophilic inflammation and reduce OCS use. Mepolizumab is a humanized monoclonal antibody that binds to and neutralizes interleukin-5, the major cytokine involved in eosinophil proliferation, activat

SUBMITTER: Pavord ID 

PROVIDER: S-EPMC9293125 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature